IBDEI11M ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,16953,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16953,1,3,0)
 ;;=3^Peliosis Hepatis
 ;;^UTILITY(U,$J,358.3,16953,1,4,0)
 ;;=4^K76.4
 ;;^UTILITY(U,$J,358.3,16953,2)
 ;;=^91041
 ;;^UTILITY(U,$J,358.3,16954,0)
 ;;=K71.50^^61^778^27
 ;;^UTILITY(U,$J,358.3,16954,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16954,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/o Ascites
 ;;^UTILITY(U,$J,358.3,16954,1,4,0)
 ;;=4^K71.50
 ;;^UTILITY(U,$J,358.3,16954,2)
 ;;=^5008799
 ;;^UTILITY(U,$J,358.3,16955,0)
 ;;=K71.51^^61^778^28
 ;;^UTILITY(U,$J,358.3,16955,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16955,1,3,0)
 ;;=3^Toxic Liver Disease w/ Chronic Active Hepatitis w/ Ascites
 ;;^UTILITY(U,$J,358.3,16955,1,4,0)
 ;;=4^K71.51
 ;;^UTILITY(U,$J,358.3,16955,2)
 ;;=^5008800
 ;;^UTILITY(U,$J,358.3,16956,0)
 ;;=K71.7^^61^778^31
 ;;^UTILITY(U,$J,358.3,16956,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16956,1,3,0)
 ;;=3^Toxic Liver Disease w/ Fibrosis & Cirrhosis of Liver
 ;;^UTILITY(U,$J,358.3,16956,1,4,0)
 ;;=4^K71.7
 ;;^UTILITY(U,$J,358.3,16956,2)
 ;;=^5008802
 ;;^UTILITY(U,$J,358.3,16957,0)
 ;;=K71.8^^61^778^35
 ;;^UTILITY(U,$J,358.3,16957,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16957,1,3,0)
 ;;=3^Toxic Liver Disease w/ Oth Disorders of Liver
 ;;^UTILITY(U,$J,358.3,16957,1,4,0)
 ;;=4^K71.8
 ;;^UTILITY(U,$J,358.3,16957,2)
 ;;=^5008803
 ;;^UTILITY(U,$J,358.3,16958,0)
 ;;=K71.9^^61^778^36
 ;;^UTILITY(U,$J,358.3,16958,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16958,1,3,0)
 ;;=3^Toxic Liver Disease,Unspec
 ;;^UTILITY(U,$J,358.3,16958,1,4,0)
 ;;=4^K71.9
 ;;^UTILITY(U,$J,358.3,16958,2)
 ;;=^5008804
 ;;^UTILITY(U,$J,358.3,16959,0)
 ;;=K75.2^^61^778^22
 ;;^UTILITY(U,$J,358.3,16959,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16959,1,3,0)
 ;;=3^Nonspecific Reactive Hepatitis
 ;;^UTILITY(U,$J,358.3,16959,1,4,0)
 ;;=4^K75.2
 ;;^UTILITY(U,$J,358.3,16959,2)
 ;;=^5008826
 ;;^UTILITY(U,$J,358.3,16960,0)
 ;;=K75.3^^61^778^13
 ;;^UTILITY(U,$J,358.3,16960,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16960,1,3,0)
 ;;=3^Granulomatous Hepatitis NEC
 ;;^UTILITY(U,$J,358.3,16960,1,4,0)
 ;;=4^K75.3
 ;;^UTILITY(U,$J,358.3,16960,2)
 ;;=^5008827
 ;;^UTILITY(U,$J,358.3,16961,0)
 ;;=K76.6^^61^778^24
 ;;^UTILITY(U,$J,358.3,16961,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16961,1,3,0)
 ;;=3^Portal Hypertension
 ;;^UTILITY(U,$J,358.3,16961,1,4,0)
 ;;=4^K76.6
 ;;^UTILITY(U,$J,358.3,16961,2)
 ;;=^5008834
 ;;^UTILITY(U,$J,358.3,16962,0)
 ;;=K74.00^^61^778^16
 ;;^UTILITY(U,$J,358.3,16962,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16962,1,3,0)
 ;;=3^Hepatic Fibrosis,Unspec
 ;;^UTILITY(U,$J,358.3,16962,1,4,0)
 ;;=4^K74.00
 ;;^UTILITY(U,$J,358.3,16962,2)
 ;;=^5159218
 ;;^UTILITY(U,$J,358.3,16963,0)
 ;;=K74.01^^61^778^15
 ;;^UTILITY(U,$J,358.3,16963,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16963,1,3,0)
 ;;=3^Hepatic Fibrosis,Early Fibrosis
 ;;^UTILITY(U,$J,358.3,16963,1,4,0)
 ;;=4^K74.01
 ;;^UTILITY(U,$J,358.3,16963,2)
 ;;=^5159219
 ;;^UTILITY(U,$J,358.3,16964,0)
 ;;=K74.02^^61^778^14
 ;;^UTILITY(U,$J,358.3,16964,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,16964,1,3,0)
 ;;=3^Hepatic Fibrosis,Advanced Fibrosis
 ;;^UTILITY(U,$J,358.3,16964,1,4,0)
 ;;=4^K74.02
 ;;^UTILITY(U,$J,358.3,16964,2)
 ;;=^5159220
 ;;^UTILITY(U,$J,358.3,16965,0)
 ;;=F20.3^^61^779^31
 ;;^UTILITY(U,$J,358.3,16965,1,0)
 ;;=^358.31IA^4^2
